The HARMONi-6 study evaluated ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non–small cell lung cancer. The combination with ivonescimab demonstrated a meaningful overall survival advantage across key patient subgroups while maintaining a manageable and generally comparable safety profile. These findings support ivonescimab plus chemotherapy as a promising new frontline treatment option for this patient population
Expert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.
Panelists consider optimal second-line therapy for patients who acquired resistance to frontline TKIs in EGFR+ advanced NSCLC.
Following treatment failure on frontline TKIs in EGFR+ advanced NSCLC, experts consider biomarker testing to inform second-line treatment.
Experts review frontline combination approaches with bevacizumab in EGFR+ advanced non–small cell lung cancer.
A comprehensive discussion on frontline treatment options for patients with EGFR+ advanced non–small cell lung cancer.
Closing out their discussion on resectable NSCLC, experts review multidisciplinary care strategies and the role of neoadjuvant therapy in patients identified for resection.
In light of evolving treatment options for resectable non–small cell lung cancer, panelists discuss biomarker testing to guide adjuvant therapy in the postoperative setting.
Experts consider if there’s a role for the continued use of first-generation TKIs in patients with resected EGFR-positive non–small cell lung cancer.
Shared insight on the clinical implications of the ADAURA trial, which tested osimertinib as adjuvant therapy following resection in patients with EGFR-positive NSCLC.
A brief discussion on the use of postoperative radiotherapy in non–small cell lung cancer following resection.
Perspectives on optimal treatment approaches for patients with resectable non–small cell lung cancer in Asia, with a focus on stage IB disease.
A comprehensive discussion on the value and limitations of tissue-based versus liquid-based biomarker testing in non–small cell lung cancer.
A broad review on how biomarker testing has impacted the clinical staging and management of non–small cell lung cancer across geographic regions.
Shared insight on how comprehensive biomarker testing should be in non–small cell lung cancer, as well as what may or may not be reimbursed.
Expert oncologists from key Asian countries share guidelines for biomarker testing in their countries and how biomarker testing is being used for non–small cell lung cancer in their region.
